None
Quote | Processa Pharmaceuticals Inc. (OTCMKTS:PCSA)
Last: | $9.94 |
---|---|
Change Percent: | -1.58% |
Open: | $9.99 |
Close: | $9.94 |
High: | $9.99 |
Low: | $9.74 |
Volume: | 800 |
Last Trade Date Time: | 09/23/2020 04:54:08 pm |
News | Processa Pharmaceuticals Inc. (OTCMKTS:PCSA)
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (PR) and one stable disease (SD) For all NGC-Cap doses, 5-Fluorouracil (5-FU) exp...
Message Board Posts | Processa Pharmaceuticals Inc. (OTCMKTS:PCSA)
Subject | By | Source | When |
---|---|---|---|
MomentumIts trading last up | Big Brother | investorshub | 04/27/2023 7:43:58 PM |
got some short data | Renee | investorshub | 04/26/2023 11:02:52 PM |
$PCSA Price now last up | parabol128 | investorshub | 04/26/2023 3:36:22 PM |
$PCSA The trading | Big Brother | investorshub | 04/25/2023 12:34:11 AM |
Good read | Big Brother | investorshub | 04/24/2023 11:12:16 PM |
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (PR) and one stable disease (SD) For all NGC-Cap doses, 5-Fluorouracil (5-FU) exp...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, will be represented at this month’s EF Hutton Annual Global Conference. According to the announcement, ke...